Triple
T32170148
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Alecensa |
E821687
|
entity |
| Predicate | instanceOf |
P0
|
FINISHED |
| Object | anaplastic lymphoma kinase inhibitor |
C43617
|
CONCEPT FINISHED |
How this triple was built (1 step)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
CD
Concept disambiguation
gpt-5-mini-2025-08-07
Target class: anaplastic lymphoma kinase inhibitor Context triple: [Alecensa, instanceOf, anaplastic lymphoma kinase inhibitor]
-
A.
tyrosine kinase inhibitor
chosen
A tyrosine kinase inhibitor is a drug that blocks the activity of tyrosine kinases—enzymes involved in cell signaling pathways—to prevent uncontrolled cell growth and proliferation, commonly used in cancer therapy.
-
B.
EGFR inhibitor
An EGFR inhibitor is a drug that blocks the epidermal growth factor receptor signaling pathway to slow or stop the growth of cancer cells that depend on this receptor.
-
C.
Janus kinase inhibitor
A Janus kinase inhibitor is a drug that selectively blocks Janus kinase (JAK) enzymes to modulate cytokine signaling and reduce inflammation or abnormal immune activity in various diseases.
-
D.
receptor tyrosine kinase
A receptor tyrosine kinase is a transmembrane protein that, upon binding an extracellular ligand, dimerizes and autophosphorylates its intracellular tyrosine residues to initiate intracellular signaling cascades regulating cell growth, differentiation, and survival.
-
E.
Bruton tyrosine kinase inhibitor
A Bruton tyrosine kinase inhibitor is a targeted small-molecule drug that blocks BTK signaling in B cells to disrupt pathways critical for their activation, proliferation, and survival, primarily used in the treatment of certain B-cell malignancies and autoimmune diseases.
- F. None of above.
Provenance (1 batch)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69f3490699a48190bbef96b198e8fade |
completed | April 30, 2026, 12:20 p.m. |
Created at: May 1, 2026, 12:33 a.m.